

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION (June 24, 2003) (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2685.2046-003	APPLICATION NO.	
	APPLICANT Richard P. Batycky		
	FILING DATE	CONFIRMATION NO.	GROUP

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
QHK	AA	4,352,789	10-05-1982	Thiel
QHK	AB	4,959,358	09-25-1990	Carey <i>et al.</i>
QHK	AC	5,002,973	03-26-1991	Zelevnick <i>et al.</i>
QHK	AD	5,049,389	09-17-1991	Radhakrishnan
QHK	AE	5,655,523	08-12-1997	Hodson <i>et al.</i>
QHK	AF	5,738,865	04-14-1998	Baichwal <i>et al.</i>
QHK	AG	5,770,559	06-23-1998	Manning <i>et al.</i>
QHK	AH	6,076,522	06-20-2000	Dwivedi <i>et al.</i>
QHK	AI	6,098,619	08-08-2000	Britto <i>et al.</i>
QHK	AJ	6,119,688	09-18-2000	Whaley <i>et al.</i>
QHK	AK	6,126,919	10-03-2000	Stefely <i>et al.</i>
QHK	AA2	6,183,782 B1	02-06-2001	Hallworth
QHK	AB2	6,221,398 B1	04-24-2001	Jakupovic <i>et al.</i>
QHK	AC2	6,245,339 B1	06-12-2001	Van Oort <i>et al.</i>
QHK	AD2	6,284,287 B1	09-04-2001	Sarlikiotis <i>et al.</i>
QHK	AE2	6,309,671 B1	10-30-2001	Foster <i>et al.</i>
QHK	AF2	6,360,743 B1	03-26-02	Andersson <i>et al.</i>
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 8/26/05
--------------------------------	----------------------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION (June 24, 2003) (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2685.2046-003	APPLICATION NO.	
	APPLICANT Richard P. Batycky		
	FILING DATE	CONFIRMATION NO.	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>JRM</i>	AR	Simons, F. E.R. <i>et al.</i> , "Can Epinephrine Inhalations Be Substituted for Epinephrine Injection in Children at Risk for Systemic Anaphylaxis?" <i>Pediatrics</i> 106(5):1040-1044 (2000).
<i>JRM</i>	AS	Gu, X. <i>et al.</i> , "Epinephrine Absorption after Different Routes of Administration in an Animal Model," <i>Biopharm. Drug Dispos.</i> 20:401-405 (1999).
<i>JRM</i>	AT	Heilborn, H. <i>et al.</i> , "Comparison of subcutaneous injection and high-dose inhalation of epinephrine - Implications for self-treatment to prevent anaphylaxis," <i>J. Allergy Clin. Immunol</i> 78(6):1174-1179 (1986).
<i>JRM</i>	AU	Warren, J.B. <i>et al.</i> , "Systemic absorption of inhaled epinephrine," <i>Clin. Pharmacol. Ther.</i> 40(6):673-678 (1986).
<i>JRM</i>	AV	Mellem, H. <i>et al.</i> , "Faster and more reliable absorption of adrenaline by aerosol inhalation than by subcutaneous injection," <i>Br. J. Clin. Pharmac.</i> 31:677-681 (1991).
<i>JRM</i>	AW	Dahlof, C. <i>et al.</i> , "Systemic absorption of adrenaline after aerosol, eye-drop and subcutaneous administration to healthy volunteers," <i>Allergy</i> 42:215-221 (1987).
<i>JRM</i>	AX	Plomley, R.F. and D. Czarny, "Inhaled adrenaline in the treatment of anaphylaxis," <i>Med. J. Aust.</i> 149:564 (1988).
<i>JRM</i>	AY	Bullock, K. And J.W. Lightbown, "The Spray-drying of Pharmaceutical Products, Part II. Certain Inorganic Salts," <i>The Chemist and Druggist</i> , CXL:147-148 (Jul-Dec 1943).
<i>JRM</i>	AZ	Bullock, K. <i>et al.</i> , "The Spray-drying of Pharmaceutical Products, Part III. Digitalis, Adrenaline and Ascorbic Acid," <i>Year-book of Pharmacy XVI</i> :221-226 (1943).
<i>JRM</i>	AR2	EpiPen® Autoinjector (Dey). Physicians' Desk Reference, 56 th ed. Montvale, New Jersey, Medical Economic Company, Inc. 2002:1236.
<i>JRM</i>	AS2	Simons, F.E.R. <i>et al.</i> , "Epinephrine absorption in children with a history of anaphylaxis," <i>J. Allergy Clin. Immunol.</i> 101(1, part 1):33-37 (1998).
<i>JRM</i>	AT2	AAAI Board of Directors, Position Statement, "The use of epinephrine in the treatment of anaphylaxis," <i>J. Allergy Clin. Immunol.</i> 94(4):666-668 (1994).
<i>JRM</i>	AU2	Simons, F.E.R., <i>et al.</i> , "Epinephrine absorption in adults: Intramuscular versus subcutaneous injection," <i>J. Allergy Clin. Immunol.</i> 108(5):871-873 (2001).

EXAMINER <i>James H. [Signature]</i>	DATE CONSIDERED <i>8/30/05</i>
---	-----------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION (June 24, 2003) (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2685.2046-003	APPLICATION NO.	
	APPLICANT Richard P. Batycky		
	FILING DATE	CONFIRMATION NO.	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AW2	Goldberg, A. and R. Confino-Cohen, "Insect sting-inflicted systemic reactions: Attitudes of patients with insect venom allergy regarding after-sting behavior and proper administration of epinephrine," <i>J. Allergy Clin. Immunol.</i> 106(6):1184-1189 (2000).	
AW2	Korenblat, P. <i>et al.</i> , "A Retrospective Study of Epinephrine Administration for Anaphylaxis: How Many Doses Are Needed?" <i>Allergy and Asthma Proc.</i> 20(6):383-386 (1999).	
AX2	Sampson, H.A. <i>et al.</i> , "Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and Adolescents," <i>New Engl. J. Med.</i> 327:380-384 (1992).	
AY2	Neugut, A.I., <i>et al.</i> , "Anaphylaxis in the United States, An Investigation Into Its Epidemiology," <i>Arch. Intern. Med.</i> 161:15-21 (2001).	
AZ2	Schwartz, H.J., <i>et al.</i> , "Is unrecognized anaphylaxis a cause of sudden unexpected death?", <i>Clin. Exp. Allergy</i> , 25(9):866-870 (1995).	
AR3	Barnard, J.H., "Studies of 400 Hymenoptera sting deaths in the United States," <i>J. Allergy Clin. Immunol.</i> , 58(5):259-264 (1973).	
AS3	Kemp, S.F. <i>et al.</i> , "Anaaphylaxis, A Review of 266 Cases," <i>Arch. Intern. Med.</i> 155:1749-1754 (1995).	
AT3	Pumphrey, R.S.H., "Lessons for management of anaphylaxis from a study of fatal reactions," <i>Clin. Exp. Allergy</i> , 30:1144-1150 (2000).	
AU3	Kaliner, M., "Allergy care in the next millennium: Guidelines for the specialty," <i>J. Allergy Clin. Immunol.</i> 99(6, pt1):729-734 (1997).	
AV3	Yunginger, J.W. <i>et al.</i> , "Fatal Food-Induced Anaphylaxis," <i>JAMA</i> , 260(10):1450-1452 (1988).	
AW3	Atkinson, T. P. And M.A. Kaliner, "Anaphylaxis," <i>Med. Clin. North Am.</i> 74(4):841-855 (1992).	
AX3	McConachie, I. "Anaesthetic dilemmas. Laryngeal oedema following anaphylactic shock," <i>Br. J. Hosp. Med.</i> 47(3):201 (1992).	
AY3	Darbar, D. <i>et al.</i> , "Epinephrine-Induced Changes in Serum Potassium and Cardiac Repolarization and Effects of Pretreatment With Propranolol and Diltiazem," <i>Am. J. Cardiol.</i> 77:1351-1355 (1996).	

EXAMINER 	DATE CONSIDERED 8/30/2005
---	------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION (June 24, 2003) (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2685.2046-003	APPLICATION NO.	
	APPLICANT Richard P. Batycky		
	FILING DATE	CONFIRMATION NO.	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>[Signature]</i>	AZ3	Barnes, P.J., "Effect of β -agonists on inflammatory cells," <i>J. Allergy Clin. Immunol.</i> 104(2, pt 2):S10-S17 (1999).
<i>[Signature]</i>	AR4	Bufarlari, A., <i>et al.</i> , "Comparative Responses to Propofol Anaesthesia alone and with α_2 -Adrenergic Medications in a Canine Model," <i>Acta Vet. Scand.</i> 37(2):187-201 (1996).
<i>[Signature]</i>	AS4	<i>British National Formulary</i> , 42:155-157 (Sep 2001).
<i>[Signature]</i>	AT4	Medihaler-Epi (3M Health Care Limited). ABPI Compendium of Data Sheets and Summaries of Product Characteristics. 2 nd ed. London: Datapharm Publications Limited 693 (1998-1999).
<i>[Signature]</i>	AU4	Soreide, E. <i>et al.</i> , "Severe anaphylactic reactions outside hospital: etiology, symptoms and treatment," <i>Acta Anaesthesiol. Scand.</i> 32:339-342 (1988).
<i>[Signature]</i>	AV4	National Advisory Committee on Immunization (NACI). "Anaphylaxis: Statement on Initial Management of in non-hospital settings," <i>Canada Communicable Disease Report</i> , 21-22:F1-F5 (1995).
<i>[Signature]</i>	AW4	AAAAI Board of Directors, Position Statement, "Anaphylaxis in Schools and Other Child-care Settings," <i>J. Allergy Clin. Immunol.</i> 102(2):173-176 (1998).
<i>[Signature]</i>	AX4	Scheuch, G. <i>et al.</i> , "Measuring <i>in vivo</i> deposition of large porous particles," Abstract-138, ISAM, 12 th International Congress. <i>J. Aerosol. Med.</i> 12(2):127 (1999).
<i>[Signature]</i>	AY4	Sabroe, R.A. <i>et al.</i> , "Therapeutics, An audit of the use of self-administered adrenaline syringes in patients with angio-oedema," <i>British Assoc. Of Dermatology</i> 146:615-620 (2002).
<i>[Signature]</i>	AZ4	Muller, U. <i>et al.</i> , "Withdrawal of the Medihaler-epi®/Adrenaline Medihaler®: comments of the Subcommittee on Insect Venom Allergy of the EAACI," <i>Allergy</i> , 53:619-620 (1998).
<i>[Signature]</i>	AR5	Primatine® Mist (Wyeth). Physicians' Desk Reference, 21th ed. Montvale, New Jersey, Medical Economic Company, Inc., 792 (2000).

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 8/30/2005
--------------------------------	------------------------------

